Biggest News Aggregation in the World
📰 Thomask Equels News

Thomask Equels News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Thomask Equels. Real-time updates on events, politics, business and more.

AIM ImmunoTech (NYSE:AIM) Shares Down 9.1%

AIM ImmunoTech Inc. (NYSE:AIM – Get Free Report)’s stock price traded down 9.1% on Tuesday . The company traded as low as $0.35 and last traded at $0.35. 344,384 shares changed hands during trading, an increase of 68% from the average session volume of 205,318 shares. The stock had previously closed at $0.39. AIM ImmunoTech […]
United States Thomask Equels Immunotech Inc Securities Exchange Commission Get Free Report Tech Trading Down

AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer | Company Announcement

Investegate announcements from AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
United States Thomask Equels Robert Edwards University Of Pittsburgh Medical Center Gynecology Reproductive Sciences Gynecologic Oncology Research At Magee Womens Hospital

AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer

OCALA, Fla., April 10, 2024 -- AIM ImmunoTech Inc.   today announced top-line interim data indicating that combining Ampligen with Keytruda in the treatment of recurrent ovarian cancer may have...
United States Robert Edwards Thomask Equels Exchange Commission Department Of Obstetrics Immunotech Inc

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

AIM ImmunoTech (AIM) Scheduled to Post Earnings on Tuesday

AIM ImmunoTech (NYSE:AIM – Get Free Report) will issue its quarterly earnings data on Tuesday, April 2nd. AIM ImmunoTech Trading Up 6.3 % Shares of NYSE AIM opened at $0.47 on Monday. AIM ImmunoTech has a one year low of $0.32 and a one year high of $0.75. The firm has a market capitalization of […]
United Kingdom United States Stewart Appelrouth Thomask Equels Immunotech Inc Renaissance Technologies

AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast

OCALA, Fla., March 26, 2024 -- AIM ImmunoTech Inc.   announced today that management will host a conference call and webcast to discuss the Company’s Q4/FY2023 operational and financial results...
United States Christopher Mcaleer Thomask Equels Immunotech Inc Chief Executive Officer Thomas Scientific Officer Christopher Mcaleer

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science